AYLA

Advaxis and Ayala Pharmaceuticals Complete Merger

Retrieved on: 
Thursday, January 19, 2023

and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.

Key Points: 
  • and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.
  • While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the name Ayala Pharmaceuticals.
  • The merged company will be focused primarily on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors.
  • As previously disclosed, the company is seeking to uplist to Nasdaq in the near future, but there is no guarantee that this effort will be successful.

AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders

Retrieved on: 
Wednesday, October 19, 2022

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders.
  • Upon completion of the merger, Ayala stockholders would own approximately 62.5% of the combined companys outstanding common stock.
  • On behalf of Ayala shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

3 Greenberg Traurig Austin Attorneys Accepted to Austin Bar Association/AYLA Leadership Academy

Retrieved on: 
Tuesday, February 15, 2022

"We are extremely proud of Nicole, Kent, and Ryan for being selected to partake in the Austin Bar Association/AYLA Leadership Academy.

Key Points: 
  • "We are extremely proud of Nicole, Kent, and Ryan for being selected to partake in the Austin Bar Association/AYLA Leadership Academy.
  • According to Austin Bar Association/AYLA, the Leadership Academy was established to assist Austin-area lawyers serve the Bar, make a difference in their community, and promote professional development.
  • "It's an honor to be selected to be part of the Austin Bar Association/AYLA 2022 Leadership Academy.
  • About Greenberg Traurig: Greenberg Traurig, LLP has more than 2400 attorneys in 42 locations in the United States, Europe, Latin America, Asia, and the Middle East.

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Thursday, January 6, 2022

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website, beginning at 7:00 AM ET on Monday, January 10, 2022.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021

Recent Business Highlights and Upcoming Milestones:

Key Points: 
  • Recent Business Highlights and Upcoming Milestones:
    Published Two Case Studies Highlighting Clinical Activity of AL101 in Desmoid Tumors in Current Oncology: In September 2021, Ayala published two case studies of adult patients with desmoid tumors treated with AL101.
  • Collaboration Revenue: Collaboration revenue was $0.6 million for the third quarter of 2021, as compared to $0.7 million for the same period in 2020.
  • G&A Expenses: General and administrative expenses were $2.2million for the third quarter of 2021, compared to $1.9 million for the same period in 2020.
  • Net Loss: Net loss was $9.8million for the third quarter of 2021, resulting in a basic and diluted net loss per share of $0.68.

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).
  • A live webcast of the fireside chat may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Retrieved on: 
Thursday, September 23, 2021

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

Retrieved on: 
Thursday, September 16, 2021

REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. The data is being presented at the 2021 ESMO Virtual Congress as an ePoster. In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.

Key Points: 
  • In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.
  • R/M ACC remains a significant area of unmet need, and I am encouraged by the preliminary results that AL101 monotherapy has demonstrated to-date.
  • The preliminary safety and efficacy data from the 6mg cohort of our ongoing ACCURACY trial of AL101 highlights a favourable profile.
  • Preliminary Safety and Efficacy Data from 6mg Cohort of ACCURACY Phase 2 Trial:
    Ayala presented new preliminary 6mg data from its ongoing ACCURACY Phase 2 clinical trial evaluating the safety and efficacy of AL101 monotherapy for the treatment of patients with R/M ACC harboring Notch-activating mutations.

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, September 2, 2021

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:
    H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
  • Citis 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021.
  • A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.